The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells
Open accessAbstract
BACKGROUND: Circulating tumor cells (CTCs) are cancer cells that can be isolated via liquid biopsy from blood and can be phenotypically and genetically characterized to provide critical information for guiding cancer treatment. Current analysis of CTCs is hindered by the throughput, selectivity and specificity of devices or assays used in CTC detection and isolation. METHODOLOGY/PRINCIPAL FINDINGS: Here, we enriched and characterized putative CTCs from blood samples of patients with both advanced stage metastatic breast and lung cancers using a novel multiplexed spiral microfluidic chip. This system detected putative CTCs under high sensitivity (100%, n = 56) (Breast cancer samples: 12-1275 CTCs/ml; Lung cancer samples: 10-1535 CTCs/ml) rapidly from clinically relevant blood volumes (7.5 ml under 5 min). Blood samples were completely separated into plasma, CTCs and PBMCs components and each fraction were characterized with immunophenotyping (Pan-cytokeratin/CD45, CD44/CD24, EpCAM), fluorescence in-situ hybridization (FISH) (EML4-ALK) or targeted somatic mutation analysis. We used an ultra-sensitive mass spectrometry based system to highlight the presence of an EGFR-activating mutation in both isolated CTCs and plasma cell-free DNA (cf-DNA), and demonstrate concordance with the original tumor-biopsy samples. CONCLUSIONS/SIGNIFICANCE: We have clinically validated our multiplexed microfluidic chip for the ultra high-throughput, low-cost and label-free enrichment of CTCs. Retrieved cells were unlabeled and viable, enabling potential propagation and real-time downstream analysis using next generation sequencing (NGS) or proteomic analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Cited by
Fundamentals and applications of inertial microfluidics: a review
Zhang, J., Yan, S., Yuan, D., Alici, G., Nguyen, N.-T., Ebrahimi Warkiani, M., & Li, W. (2016) · Lab on a Chip · doi:10.1039/c5lc01159k · Cited by 1,017
Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics
Warkiani, M. E., Khoo, B. L., Wu, L., Tay, A. K. P., Bhagat, A. A. S., Han, J., & Lim, C. T. (2016) · Nature Protocols · doi:10.1038/nprot.2016.003 · Cited by 548
Self-citationCirculating tumor cell technologies
Ferreira, M. M., Ramani, V. C., & Jeffrey, S. S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.007 · Cited by 511
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 355
Khoo, B. L., Grenci, G., Lim, Y. B., Lee, S. C., Han, J., & Lim, C. T. (2018) · Nature Protocols · doi:10.1038/nprot.2017.125 · Cited by 172
Self-citation
Metadata
- Authors
- Khoo, B. L., Warkiani, M. E., Tan, D. S.-W., Bhagat, A. A. S., Irwin, D., Lau, D. P., Lim, A. S. T., Lim, K. H., Krisna, S. S., Lim, W.-T., Yap, Y. S., Lee, S. C., Soo, R. A., Han, J., & Lim, C. T.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-07
- Volume
- 9
- Issue
- 7
- Pages
- e99409
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2143843041
- Cited by
- 206
- References
- 1
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0099409
- The paper
- Khoo, B. L., Warkiani, M. E., Tan, D. S.-W., Bhagat, A. A. S., Irwin, D., Lau, D. P., Lim, A. S. T., Lim, K. H., Krisna, S. S., Lim, W.-T., Yap, Y. S., Lee, S. C., Soo, R. A., Han, J., & Lim, C. T. (2014). Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0099409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.